@inproceedings{inproceedings, title = {{An updated cost-effectiveness analysis of evolocumab therapy for reducing cardiovascular events in very high-risk patients with atherosclerotic cardiovascular disease according to the 2018 ACC/AHA guideline}}, publisher = {{Elsevier BV}}, url = {{}}, year = {{2019}}, month = {{5}}, author = {{Fonarow GC and van Hout B and Villa G and Arellano J and Lindgren P}}, doi = {{10.1016/j.jacl.2019.04.054}}, volume = {{13}}, journal = {{Journal of Clinical Lipidology}}, issue = {{3}}, pages = {{e31-e31}}, note = {{Accessed on 2024/12/22}}}